* BioNTech strategy head says price will reflect investors' risk Says production ramp-up will continue throughout 2021 * Volumes will be significant in H1, but scaling up also in H2 * CEPI head: BioNTech, Pfizer received no "substantial" subsidies BioNTech, first in the race to produce evidence of a working Covid-19 vaccine, is planning to price the two-shot regimen below "typical market rates" and would differentiate pricing between countries or regions. Speaking at a Financial Times online event, the German biotech firm's strategy head Ryan Richardson said the price tag of the vaccine, which is co-developed with Pfizer and which has yet to win regulatory approval, would reflect the fi
Hence then, the article about biontech to price vaccine below market rates differentiate between regions was published today ( ) and is available onGulf Times ( Qatar ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( BioNTech to price vaccine below market rates, differentiate between regions )